However, using scRNASeq data from breast tumors, we mainly observed an expression of CMKLR1 in a subset of TAM C1QC+ that expressed usual M2 signature, including high expression of CD14 and CD163, whereas CMKLR1 expression was low in a subset of TAM ISG15+ that expressed classical M1 signature (36). Here, CD163 is linked to breast neoplasm.